Form 4: Amneal Pharmaceuticals Director Equity Transaction

Director Jeffrey P. George acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Summary

• Director Jeffrey P. George exercised and converted 34,819 restricted stock units (RSUs) into Class A Common Stock on May 7, 2026.
• The reporting person was granted 19,824 new restricted stock units on May 6, 2026.
• Following these transactions, the director holds a total of 344,614 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity management.

Positives

• Director maintains a significant equity stake of 344,614 shares, aligning interests with shareholders.

Negatives

• None identified.

Risks

• Future vesting of the newly granted 19,824 RSUs is subject to the timing of the company's annual meeting of stockholders.

Future Outlook

The newly granted 19,824 restricted stock units are scheduled to vest on the later of the day preceding the first annual meeting of stockholders following the grant date or the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that routine equity vesting for directors is standard corporate governance practice in the pharmaceutical sector, reflecting typical long-term incentive compensation structures.

Comparison to Industry Standards

• The transaction follows standard SEC reporting requirements for executive and director compensation.
• Equity-based compensation for board members is consistent with peer pharmaceutical companies like Teva or Viatris.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity compensation rather than a market sale or purchase.

Next Steps

• Vesting of the 19,824 restricted stock units granted on May 6, 2026, contingent on future annual meeting dates.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Insider Trading, Form 4, Equity Compensation, Director Ownership